Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Down 18.4% in December

by · The Markets Daily

Dogwood Therapeutics, Inc (NASDAQ:DWTX – Get Free Report) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 50,720 shares, a drop of 18.4% from the November 30th total of 62,139 shares. Approximately 2.3% of the company’s stock are short sold. Based on an average daily trading volume, of 40,958 shares, the short-interest ratio is currently 1.2 days. Based on an average daily trading volume, of 40,958 shares, the short-interest ratio is currently 1.2 days. Approximately 2.3% of the company’s stock are short sold.

Analyst Ratings Changes

Several analysts recently issued reports on the company. HC Wainwright increased their price objective on Dogwood Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Monday, December 22nd. Finally, Wall Street Zen downgraded Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.00.

Read Our Latest Report on DWTX

Dogwood Therapeutics Stock Performance

Shares of DWTX traded up $0.02 during trading hours on Wednesday, hitting $4.16. 10,847 shares of the company were exchanged, compared to its average volume of 60,977. The firm’s 50 day moving average is $5.78 and its 200-day moving average is $5.37. Dogwood Therapeutics has a 52 week low of $1.87 and a 52 week high of $29.28.

Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($8.20) EPS for the quarter, missing the consensus estimate of ($1.23) by ($6.97). As a group, equities research analysts forecast that Dogwood Therapeutics will post -6.43 earnings per share for the current fiscal year.

About Dogwood Therapeutics

(Get Free Report)

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.

See Also